Literature DB >> 15832591

Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use.

R Verrando1, G Robaeys, C Matheï, F Buntinx.   

Abstract

Heroin addiction is a chronic relapsing disease that is difficult to cure, but stabilisation and harm reduction can importantly increase the life time expectancy and the quality of life of the patient, his immediate vicinity and society in general. Currently, no proven effective pharmacological interventions are available for cocaine addiction, and treatment has to rely on existing cognitive behaviour therapies combined with contingency management strategies. Substitution therapy, however, is effective in caring for heroin addicts. Methadone is a synthetic opioid that counteracts withdrawal symptoms of heroin. Buprenorphine is a derivative of the morphine alkaloid, thebaine, and is a partial opioid agonist at the micro opioid receptor in the nervous system. A substitution treatment program effectively reduces and often eliminates heroin injection behaviour, rendering patients more socially stabilised. Reduction in the number of viral co-infections can be observed. Methadone undergoes oxidative biotransformation in the liver, but is also stored in the liver and released into the blood in unchanged form. The usual dose can be continued in patients with stable chronic liver disease, including advanced cirrhosis. In acute liver disease or acute decompensation of chronic liver disease, close clinical observation for signs of narcotic overdose or withdrawal is necessary. A modest alteration in methadone dose may be appropriate for some patients. Buprenorphine can cause liver dysfunction after sublingual and even more after intravenous administration. It is advised to follow the liver function during buprenorphine treatment and to warn the clients for intravenous use of buprenorphine. Neither methadone nor buprenorphine do influence the effect of interferon and ribavirin during the treatment of chronic hepatitis C patients. It may be necessary to increase the dosage of methadone during interferon treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832591

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN: 1784-3227            Impact factor:   1.316


  7 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

Review 3.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Authors:  Jean Bonhomme; Ruth S Shim; Richard Gooden; Dawn Tyus; George Rust
Journal:  J Natl Med Assoc       Date:  2012 Jul-Aug       Impact factor: 1.798

Review 5.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

7.  Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.

Authors:  Shiow-Ling Wu; Sheng-Chang Wang; Hsiao-Hui Tsou; Hsiang-Wei Kuo; Ing-Kang Ho; Sheng-Wen Liu; Ya-Ting Hsu; Yao-Sheng Chang; Yu-Li Liu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.